Re Acolyte Biomedica

Angle PLC
31 May 2005


For immediate release                                                31 May 2005


                                  ANGLE plc

         Acolyte Biomedica launches BacLite(R) Rapid MRSA test


ANGLE plc ('ANGLE') is pleased to announce that its venture company Acolyte
Biomedica Ltd ('Acolyte') has successfully launched its BacLite(R) Rapid MRSA '
superbug' test and that Salisbury District Hospital takes delivery of the first
system today.

The BacLite(R) system uses AK Rapid(R) technology developed by the Defence
Science and Technology Laboratories (Dstl), an agency of the Ministry of Defence
at Porton Down, Wiltshire.

Giving same day results, the BacLite(R) Rapid MRSA test will allow hospitals to
screen patients and hospital workers for the presence of the superbug. This
information will enable infection control teams to act quickly to prevent
hospital acquired infection.

In the UK, the combination of high bed occupancy and very infectious strains of
the superbug means that traditional screening methods are too slow for maximum
effect. Healthcare acquired infections, of which MRSA is the most significant,
are estimated to cause 5,000 deaths in the UK each year.  By being able to act
quickly, hospitals can reduce significantly the incidence of mortality and
morbidity. In addition, MRSA costs the NHS around £1 billion per annum, so
reducing the incidence of the infection will have a major financial impact.

The final evaluation of the BacLite(R) system at three UK hospital laboratories,
including Salisbury District Hospital, showed the test can achieve in five hours
what current microbiological methods take two days to deliver. Conclusions to
studies illustrate the confidence that medical staff have when using BacLite(R)
Rapid MRSA test information for admitting patients; the probability that a
negative result was correct (negative predictive value) was over 99%.

Commenting on the launch, Dr Bill Mullen, CEO of Acolyte said:

'Identification of MRSA carriers is critical in overcoming the MRSA problem in
our hospitals. We expect this test to offer a rapid and cost effective screening
method at an important time in the fight against MRSA.'

Andrew Newland, CEO of ANGLE said:

'This launch is a significant milestone for Acolyte and underlines the high
value of the technology and the clinical importance of such a testing system. We
at ANGLE are  proud to have played a pivotal role in leading the development of
Acolyte and, in so doing, bringing this vital diagnostic technology to market.

MRSA is just the first application of the technology, which in due course will
be applied to the diagnosis of a wide range of other serious infections.'

                                     -ENDS-

For further information

ANGLE plc                                                     [phone]
Andrew Newland, Chief Executive
Dawson Buck, Deputy Chief Executive

Buchanan Communications                                      [phone]
Suzanne Brocks, James Strong

Note to editors:

ANGLE

Founded in 1994, ANGLE is an international venture management and consulting
company focusing on the commercialisation of technology and the development of
technology-based industry. ANGLE creates, develops and advises technology
businesses on its own behalf and for its clients. ANGLE is listed on AIM
(AGL.L); further information can be found on www.ANGLEplc.com

Acolyte Biomedica Ltd was founded in February 2000 by ANGLE and is 1 of the 8
venture companies developed under ANGLE's Progeny(R) programme to date. Dr Bill
Mullen, Acolyte's CEO is a former ANGLE senior executive.  Acolyte signed its
first agreement with Dstl (then DERA) later that year.  The Company has received
UK Government and venture funding from ANGLE, BioProjects International, Porton
Capital and Partnerships UK. ANGLE retains a 10.9% equity holding in Acolyte.

Acolyte employs 22 staff in its laboratories at Porton Down, Wiltshire, UK.  Its
website is www.acolytebiomedica.com

BacLite(R) MRSA is an instrument-based system for rapid and cost-effective
screening of the most prevalent hospital-acquired infection.

                      This information is provided by RNS
            The company news service from the London Stock Exchange